Protalix Biotherapeutics Inc. (PLX)
NYSE · Healthcare
Protalix Biotherapeutics Inc. Operating Income 2009–2025
Protalix Biotherapeutics Inc. annual/quarterly operating income history and growth rate from 2009 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Protalix Biotherapeutics Inc. operating income for the quarter ending March 31, 2026 was 21.1 M, a 610.16% decrease year-over-year.
- Protalix Biotherapeutics Inc. operating income for the twelve months ending March 31, 2026 was 20.3 M, a 492.04% decrease year-over-year.
- Protalix Biotherapeutics Inc. annual operating income for 2025 was -5.5 M, a 240.41% decrease from 2024.
- Protalix Biotherapeutics Inc. annual operating income for 2024 was 3.9 M, a 62.55% decrease from 2023.
- Protalix Biotherapeutics Inc. annual operating income for 2023 was 10.5 M, a 180.37% decrease from 2022.
- Protalix Biotherapeutics Inc. annual operating income for 2022 was -13.0 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Protalix Biotherapeutics Inc. Operating Income — FAQ
Protalix Biotherapeutics Inc. (PLX) operating income over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
What is Protalix Biotherapeutics Inc.'s operating income?
Protalix Biotherapeutics Inc. (PLX) reported operating income of -$6M for fiscal 2025.
Where can I see PLX's operating income history?
The chart and table above show Protalix Biotherapeutics Inc.'s operating income by year and by quarter, including the growth rate.